What a follow-up handover actually needs to contain
Long-term follow-up for non-small cell lung cancer is not a single appointment. It is a sequence of decisions: how often to image, which scans, whether any tissue or blood test should be repeated, whether a prior treatment can continue, and who owns each decision. Each of those decisions depends on facts that live in different documents. A discharge summary alone rarely carries them.
The core file has four layers. The first is the diagnostic pathology report, including the histologic type and any biomarker results that were tested. The second is the treatment history: surgery, radiotherapy, chemotherapy, targeted therapy or immunotherapy, with dates, agents and the reason each was stopped or changed. The third is the imaging trail, ideally with the actual images or a disc, not only the written report. The fourth is the current clinical picture: symptoms, performance status, other conditions and current medicines.
Why the layers matter separately: a receiving clinician who has only the last scan report cannot tell whether a stable finding is new or has been present for two years. A clinician who has only the treatment list cannot judge whether a prior regimen was stopped for progression, toxicity or completion. Each missing layer changes the question that has to be asked next.
Pathology and biomarker reports: checking completeness
Biomarker results are the records most frequently missing from an overseas handover, because testing may have been done at a different laboratory from the one that issued the original diagnosis, and the report may never have been given to the patient. Ask specifically for the molecular or genomic report, not just the pathology summary. If testing was done, the report should state which markers were assessed and the result for each.
If no biomarker testing was performed, that is itself a fact the receiving team needs. It is not the same as a negative result. The distinction changes what a clinician may want to discuss next, and it is a question for that clinician, not something to resolve by reading a general article.
Two practical points. First, ask for reports in their original language plus a translation if the receiving team does not read that language; a translated summary without the original can lose the exact wording of a result. Second, ask whether the laboratory can issue a re-issued or certified copy if yours is lost. Whether a Chinese hospital will accept a foreign laboratory report, or ask for re-testing of stored tissue, is a question for that hospital, not a general rule.
Previous cancer therapy: what the next team needs to know and why
For non-small cell lung cancer, the prior treatment history is not background information. It shapes which options remain reasonable and which have already been tried. The receiving team needs the drug names, the dates of each cycle or course, the dose if available, the response as documented at the time, and the reason treatment ended. "Completed planned course" and "stopped because the tumour grew" lead to very different next questions.
Radiotherapy records deserve the same care. The site treated, the total dose and the fractionation belong in the file, because later decisions about further radiation to the same area depend on what was already delivered. If you do not have the radiotherapy summary, ask the treating centre for it.
A common gap is the reason for a change. Patients often remember that a treatment was stopped but not whether it was toxicity, progression or a planned switch. If the reason is not documented, say so plainly rather than guessing. A receiving clinician can work with an acknowledged gap; a wrong reason in a summary is harder to correct later.
One administrative example: if you are assembling this file for a review in China, ask the coordinating team which documents the named hospital wants in original, which as a copy, and whether a translation is needed before the appointment. Getting that list in writing before you send anything avoids repeated courier rounds.
Local and systemic options: what the receiving team decides, not the file
Patients often arrive at follow-up hoping the records will produce a clear answer about whether surgery, radiotherapy or a systemic therapy is still possible. Records inform that discussion; they do not settle it. Suitability depends on the current extent of disease, the patient's general condition, organ function, prior treatments and the judgement of the treating team. A records-based review can identify what is missing and what questions to ask, but it does not establish eligibility for a procedure or a therapy.
This distinction matters most when a patient is considering travel specifically to access an option. Ask the hospital, in writing, what it can and cannot confirm from records alone, and what would need to be assessed in person. Do not treat a positive-sounding reply to an enquiry as confirmation that a treatment will be offered.
For follow-up specifically, the useful question is narrower: given this history, what does the receiving clinician want to monitor, and what would prompt a change in plan? That is a clinical judgement for the treating team. Your job in the handover is to make sure they have the material to make it.
Follow-up in China after treatment abroad: questions to settle first
If the plan is to continue follow-up in China after treatment elsewhere, several practical questions should be answered before you commit to a schedule. Who will be the responsible clinician for the follow-up, and how do you reach them between visits? How are imaging results stored and shared, and can you obtain copies for a team in another country later? If a scan finding needs discussion, is there a route to a multidisciplinary review?
Language is part of this. Ask whether reports will be issued in a language you can read, or whether interpretation is needed at each visit. Ask how prescription continuity works if you take a long-term medicine, and what documentation the hospital wants for medicines you bring with you. These are administrative questions with real clinical consequences if they are left to the day of the appointment.
Do not assume that a follow-up interval used in one health system will be adopted in another. Ask the receiving clinician what interval they recommend for your situation and why. If you are comparing two possible follow-up arrangements, ask each one the same set of questions so the answers can be compared directly.
- Who is the named responsible clinician for follow-up, and how are they contacted between visits?
- How are imaging discs and reports stored, and how do you obtain copies later?
- What language will reports and consultations be in, and is interpretation arranged?
- How is a long-term medicine continued, and what documentation is needed for medicines brought in?
- What would prompt an earlier review than the planned interval?
Preparing the handover and the next step
Build the file in the order the receiving team will read it: a one-page summary of the diagnosis and treatment timeline, then the supporting reports behind it. Keep the original documents and send copies unless a hospital asks for originals. Label every document with the date and the issuing institution; undated reports are a frequent source of confusion in a handover.
If you are considering follow-up or a records-based opinion in China, a short initial enquiry is enough to start. Share a brief summary of the diagnosis, the treatment received and your main question; the team can then tell you which records are relevant and what the next step would be. An initial enquiry is free, and it does not commit you to buying a proxy consultation or any other service. The hospital, not the coordinating team, decides whether it can accept the case and what it can confirm from records.
For patients whose treatment included lung surgery, the relevant procedure reference on this site is lung lobectomy, which removes a lung lobe and is different from removal of an entire lung. That page is a starting point for understanding the procedure; it does not replace your treating team's advice about your own follow-up.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.